Ghrh antagonist

1 study on Ghrh antagonist curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on Ghrh antagonist. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

Ghrh antagonist studies and clinical research

2026-04-03 PubMed · preclinical animal · n preclinical

GHRH Antagonist JMR-132 Blocks Both ER-Positive and ER-Negative Breast Cancer Cell Proliferation

**GHRH antagonism via JMR-132 may represent a receptor-status-agnostic therapeutic axis in breast cancer**, addressing a major clinical gap: ER-negative tumors have few hormone-based treatment options. The dual activi…

Research tools

Free, no account — handy when you're working with Ghrh antagonist.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$14 monthly or $88/year

Create an account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

Ghrh antagonist studies and clinical research

GHRH Antagonist JMR-132 Blocks Both ER-Positive and ER-Negative Breast Cancer Cell Proliferation

Research tools